Drug Trial Radar · NCT05138887
A Study for Assessing the Efficacy and Safety of BH4 in Radiation Enteritis
Last checked: Nov 20, 2026Latest source record: Mar 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
366
Planned (sponsor's estimate)
Start
Mar 1, 2022
Primary completion
Oct 1, 2023
Study completion Mar 1, 2024
Sponsor
- Lead sponsor
- West China Second University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This present study envisaged a single-center, prospective, open-label, placebo and randomized controlled phase II clinical study to assess the efficacy and Safety of Tetrahydrobiopterin in Treating Radiation Enteritis in Gynecological Cancer Patients.
Conditions
- Radiation Enteritis
Interventions
TetrahydrobiopterinDrug
The experimental group1 was administered BH4 orally with a dose of 2 mg/kg.d, once per day, and the experimental group 2 was administered BH4 orally witha dose of 5 mg/kg.d, two times a day (If the drug dose is within the range of 151-250mg, the drug dose is 200mg) or three times a day (If the drug dose is within the range of 251-350mg, the drug dose is 300mg). The oral administration of pills was started on the same day of the first radiation treatment, and ended three months after the treatment ended.
Primary outcomes
What the sponsor says the trial is designed to measure.
- acute radiation-induced proctitis (ARP) incidenceTime frame: up to 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
est China Second Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.